drugset / Trial / NCT04217057
Imaging CCR2 Receptors With 64Cu-DOTA-ECL1i in Head and Neck Cancer
Phase 1
Terminated
11 enrolled
Washington University School of Medicine
National Institute for Biomedical Imaging and Bioengineering (NIBIB) · collabNational Institutes of Health (NIH) · collab
NaSingle-groupOpen-labelDiagnostic
Summary
CCR2 is a significant prognostic biomarker in head and neck cancer. Currently there is no clinical biomarker to study CCR2, its prognostic significance or to select patients for CCR2-targeted therapy and to monitor response to such therapy. The investigators have developed a CCR2 specific PET radiotracer based on the peptide, ECL1i (d(LGTFLKC)) and radiolabeled with 64Cu (64Cu-DOTA-ECL1i). The investigators have found that 64Cu-DOTA-ELC1i specific binding has been demonstrated in human head and neck cancer tissue.
Timeline
- Start
- 2020-02-07
- Primary completion
- 2023-02-07
- Completion
- 2023-02-07
Outcome
Outcome not reported
Stopped (Business): “Insufficient funding/staff”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 64Cu-DOTA-ECL1i | Peptide | — | — |